Highlight
1. Renal denervation (RDN) achieved significantly greater reductions in both 24-hour ambulatory and office systolic blood pressure at 24 months compared with sham control.
2. The control group increased antihypertensive medication use more than the RDN group over 24 months.
3. No serious adverse renal events, including renal artery stenosis, were reported through 24 months, confirming long-term safety.
4. Sensitivity analyses accounting for crossover patients validated the robustness of the blood pressure benefits with RDN.
